Long-Term Monitoring: The Yearly Workup

Cycle-level bloodwork catches acute shifts. It's the right tool for "did this eight-week sermorelin run push my IGF-1 too high?" or "is my HbA1c drifting on my GLP-1 cycle?"

It's not the right tool for "after three years of on-and-off peptide use, is anything quietly moving in a direction I don't want?" For that you need an annual workup — broader than a cycle check, focused on slow-drift markers that a four-week window can't resolve.

This article is for people who've been in the community long enough that "chronic user" is accurate: multiple cycles a year, or continuous protocols on one or more peptides. If that's you, the cycle-level panel isn't enough.

Why annual matters

Some problems develop on a timescale that's invisible inside a single cycle:

• Glucose drift — HbA1c reflects three months. Moving from 5.2% to 5.8% over two years is meaningful and easy to miss.
• Lipid shifts — LDL creeping up across years.
• Thyroid remodeling — TSH patterns that emerge only with sustained load.
• IGF-1 normalization — whether your GH axis returns to true baseline between cycles, or whether each cycle leaves a slightly higher floor.
• Kidney function — eGFR declines slowly; a 5-point drop in a year is worth noticing.
• Inflammation — baseline CRP that's been slowly elevating.
• Bone density — relevant for long-term GLP-1 users with significant weight loss.
• Cardiac structure — for users on long-term high-dose GH peptides.

None of these show up in a single cycle's data. All of them show up if you compare year-to-year data.

The annual panel

This goes beyond the cycle panel. Run it once a year at roughly the same time — ideally in a non-cycling window, so you're measuring your "clean" baseline rather than a mid-protocol snapshot.

Category	Tests	What you're watching for
Metabolic — glucose	Fasting glucose, HbA1c, fasting insulin, HOMA-IR	Insulin resistance creeping up
Metabolic — lipids	Full lipid panel (LDL, HDL, TG), ApoB, Lp(a) once	ApoB is the better LDL readout; Lp(a) is once-in-a-lifetime useful
Endocrine — GH axis	IGF-1, IGFBP-3	Floor drift over years
Endocrine — thyroid	TSH, free T3, free T4, reverse T3, TPO antibodies (once)	Subclinical shifts
Endocrine — sex hormones	Total + free testosterone, SHBG, estradiol (sensitive assay), DHEA-S, prolactin	Age-appropriate trajectory vs. peptide-induced shift
Kidney	CMP (BUN, creatinine, eGFR), cystatin C, urine albumin/creatinine	Filtration drift
Liver	ALT, AST, GGT, alkaline phosphatase, bilirubin	Hepatic stress
Hematologic	CBC with differential, ferritin, reticulocyte count if hematocrit trending up	Polycythemia, iron shifts
Inflammation	hs-CRP, fibrinogen, homocysteine	Systemic load
Nutritional	Vitamin D (25-OH), B12, folate, magnesium (RBC), zinc	Common deficiencies, worse in undereaters
Cardiac markers	Troponin (once, for baseline), BNP if any cardiac symptoms	Detecting subclinical issues

On top of that, the imaging / structural checks that matter at the annual level:

Check	Frequency	Relevant for
Blood pressure	At every check, logged	Everyone
Resting heart rate (7-day average)	Logged	Everyone; especially GH axis and melanocortin users
DEXA scan (body comp + bone density)	Annually if on long-term GLP-1 or underweight	Chronic GLP-1 users, lean users on GH stacks
Echocardiogram	Baseline + every 2-3 years	Long-term high-dose GH peptide users
Skin check with dermatologist	Annually	Melanotan II users, anyone with atypical moles
Colonoscopy	Per age guidelines (don't skip)	Everyone; GLP-1 and GH users in particular, age-appropriate
Abdominal ultrasound	If symptoms, or every 2–3 years for long-term GLP-1 users	Gallbladder surveillance

Sex-specific additions

For men:

• PSA annually over 45 (earlier with family history). GH axis peptides and IGF-1 analogs especially — the prostate is IGF-1-sensitive tissue.
• Testicular self-exam monthly. Not specifically peptide-related, but basic hygiene.

For women:

• Mammography per age guidelines — don't push it back. The breast-IGF-1 link means this matters more for long-term GH-axis users.
• Pelvic exam / cervical screening per guidelines.
• If on GLP-1 during any reproductive-age year: confirmed stop 2 months before any attempt to conceive.

Reading the annual picture

Single-year snapshots are less informative than trend lines. The value of the annual workup is unlocked when you have three or four years of data to compare.

Look for:

• Any single marker drifting in one direction for 3+ years. Even if every individual value is still "in range," a consistent drift is a signal.
• Ratios that changed — triglyceride/HDL, HOMA-IR, free T3 / reverse T3.
• Year-over-year IGF-1 — if it's creeping up in non-cycling windows, the GH axis isn't fully resetting. That's a cue to lengthen off-cycle windows, not increase doses.
• Hematocrit trend — a slow rise over years is worth attention even if you're not at a hard threshold yet.
• Resting HR and BP over time — most people's go up with age, but the rate of change matters.

The "should I keep doing this at all?" question

At some point every long-term user should ask, honestly: is the benefit I'm getting still worth the monitoring load and the cumulative biological intervention? The answer is often yes. Sometimes it's no. The annual workup is the data you need to answer it rather than guess.

Signs the answer might be no:

• You're running peptides out of habit rather than for a specific benefit you can name.
• Your markers are slowly drifting across multiple systems.
• You've escalated doses over years without escalating results.
• You're spending more on compounds and lab work than you can justify.

None of those automatically mean stop. They're prompts to take a longer break, drop protocols back to a minimum, and see what your baseline looks like without intervention.

When to stop and see a doctor

If your annual workup shows a marker that's moved into a clinically relevant range — new glucose dysregulation, significant lipid elevation, emerging thyroid abnormality, hematocrit above 54%, LDL/ApoB meaningfully elevated from baseline, or any imaging finding — bring a clinician into the loop. Chronic users benefit disproportionately from having a primary care relationship where the clinician knows what you're doing. Finding one who understands peptides is easier than it was five years ago, and worth the search.

Where to go next

• Bloodwork panels for peptide users is the cycle-level companion to this article.
• Cycling principles covers on/off structure, which is the biggest lever for keeping long-term use sustainable.
• Red flags: when to stop a protocol immediately for mid-cycle warning signs.

---

This is educational content, not medical advice. Abnormal labs or symptoms warrant consultation with a qualified healthcare provider.